Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

T1D Exchange

Eli Lilly HQ

Lilly set to launch Lantus biosimilar in the US next year

Settlement ends the company's legal dispute with Sanofi

- PMLiVE

Jardiance survival data wows diabetes conference

BoehringerIngelheim and Eli Lilly release top-line findings from landmark trial at EASD

- PMLiVE

New data arms Novo Nordisk for insulin battle with Sanofi

Tresibaand Xultophy boosted by studies presented at EASD 

- PMLiVE

Lilly’s Cyramza not backed in draft NICE guidance

Institute says drug is not a cost-effective use of NHS resources

Sanofi and Google partner on digital health in diabetes

Aimto develop new patient tools by harnessing data and miniaturised tech

- PMLiVE

Novo Nordisk acquires two US biopharma companies

Strikes deals with Calibrium LLC and MB2

- PMLiVE

FDA clears Jardiance combo for type 2 diabetes

Combination treatment Synjardy is fifth drug to come from Boehringer/Lilly diabetes alliance

- PMLiVE

Novo Nordisk plans $2bn expansion of its diabetes facilities

Comes as the Danish firm prepares to move oral semaglutideinto phase III trials

Eli Lilly HQ

Lilly UK reappoints Hanover for public affairs account

Med comms firm will also work with the pharma company on digital and corporate communications

Eli Lilly HQ

Lilly and Boehringer launch Lantus biosimilar in UK

Competition in the insulin drug market begins to heat up

Could ‘around the pill’ solutions be the key to effective diabetes management?

Published in pharmaphorum July 2015 by Julie Denny

Research Partnership

- PMLiVE

Novo Nordisk’s Victoza fails type 1 diabetes trial

Danish firm’s hopes dashed by latest data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links